{"entity":{"id":"nct06769152","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors","aka":[],"tldr":"A phase 2 trial of HLX43 in cervical cancer and ovarian cancer, run by Shanghai Henlius Biotech, now recruiting.","summary":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors is a phase 2 interventional study registered as NCT06769152 by Shanghai Henlius Biotech, with 190 participants planned, started 2025-02-20 and due to reach its primary completion in 2026-12-31. Interventions recorded: HLX43. Conditions listed: Cervical Cancer, Ovarian Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06769152","url":"https://clinicaltrials.gov/study/NCT06769152"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cervical","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["hlx43"],"companies":["henlius"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06769152","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Recurrent/Metastatic Gynecological Malignant Tumors Failed or Intolerance to Standard First-Line Therapy","sponsor":"Shanghai Henlius Biotech","enrolled":190,"outcomes":[]},"route":"/trials/nct06769152/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"hlx43","kind":"drug","name":"HLX43","route":"/drugs/hlx43/"}],"company":[{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/"}]}}